Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-05-21 10:12 am Purchase | 2024-05-21 | 13G | Reneo Pharmaceuticals, Inc. RPHM | BML Investment Partners, L.P. | 369,296 11.000% | 199,873 (+117.97%) | Filing History |
| 2024-05-21 10:01 am Purchase | 2024-05-13 | 13G | AVROBIO, Inc. AVRO | BML Investment Partners, L.P. | 430,689 11.500% | 63,886 (+17.42%) | Filing History |
| 2024-04-29 4:10 pm Purchase | 2024-04-18 | 13G | Adverum Biotechnologies, Inc. ADVM | BML Investment Partners, L.P. | 1,141,000 5.500% | 655,575 (+135.05%) | Filing History |
| 2024-04-02 4:36 pm Purchase | 2024-03-22 | 13G | Instil Bio, Inc. TIL | BML Investment Partners, L.P. | 346,190 5.300% | 346,190 (New Position) | Filing History |
| 2024-03-19 4:29 pm Purchase | 2024-03-18 | 13G | CYTEIR THERAPEUTICS INC CYTT | BML Investment Partners, L.P. | 3,818,464 10.600% | 348,456 (+10.04%) | Filing History |
| 2024-02-08 11:14 am Purchase | 2024-02-07 | 13G | Aclaris Therapeutics, Inc. ACRS | BML Investment Partners, L.P. | 9,395,934 13.300% | 4,895,934 (+108.80%) | Filing History |
| 2024-02-07 2:11 pm Purchase | 2023-12-31 | 13G | Tourmaline Bio, Inc. TRML | BML Investment Partners, L.P. | 245,500 1.000% | 245,500 (New Position) | Filing History |
| 2024-02-07 1:40 pm Purchase | 2023-12-31 | 13G | CYTEIR THERAPEUTICS INC CYTT | BML Investment Partners, L.P. | 3,470,008 9.600% | 734,035 (+26.83%) | Filing History |
| 2024-02-07 1:18 pm Sale | 2023-12-31 | 13G | Surrozen, Inc. SRZN | BML Investment Partners, L.P. | 0 0.000% | -111,269 (Position Closed) | Filing History |
| 2024-02-07 1:08 pm Sale | 2023-12-31 | 13G | ARCA biopharma, Inc. ABIO | BML Investment Partners, L.P. | 58,911 4.900% | -12,611 (-17.63%) | Filing History |
| 2024-02-07 12:55 pm Sale | 2023-12-31 | 13G | Tilly's, Inc. TLYS | BML Investment Partners, L.P. | 0 0.000% | -1,234,844 (Position Closed) | Filing History |
| 2024-02-07 12:16 pm Purchase | 2023-12-31 | 13G | Enliven Therapeutics, Inc. ELVN | BML Investment Partners, L.P. | 50,000 0.100% | 50,000 (New Position) | Filing History |
| 2024-02-07 11:53 am Purchase | 2023-12-31 | 13G | Climb Bio, Inc. CLYM | BML Investment Partners, L.P. | 2,350,682 8.500% | 453,068 (+23.88%) | Filing History |
| 2024-02-07 11:36 am Sale | 2023-12-31 | 13G | Adverum Biotechnologies, Inc. ADVM | BML Investment Partners, L.P. | 485,425 2.300% | -244,593 (-33.51%) | Filing History |
| 2024-02-07 11:14 am Purchase | 2023-12-31 | 13G | CalciMedica, Inc. CALC | BML Investment Partners, L.P. | 220,424 2.100% | 220,424 (New Position) | Filing History |
| 2024-02-07 10:50 am Sale | 2023-12-31 | 13G | Quince Therapeutics, Inc. QNCX | BML Investment Partners, L.P. | 0 0.000% | -1,841,301 (Position Closed) | Filing History |
| 2024-02-07 10:32 am Purchase | 2024-02-07 | 13G | AVROBIO, Inc. AVRO | BML Investment Partners, L.P. | 366,802 9.900% | 36,353 (+11.00%) | Filing History |
| 2024-02-07 09:25 am Unchanged | 2023-12-31 | 13G | Atea Pharmaceuticals, Inc. AVIR | BML Investment Partners, L.P. | 5,602,079 6.700% | 0 (Unchanged) | Filing History |
| 2024-02-07 09:14 am Purchase | 2023-12-31 | 13G | Atea Pharmaceuticals, Inc. AVIR | BML Investment Partners, L.P. | 5,602,079 6.700% | 1,418,434 (+33.90%) | Filing History |
| 2024-01-16 5:54 pm Purchase | 2024-01-10 | 13G | Reneo Pharmaceuticals, Inc. RPHM | BML Investment Partners, L.P. | 169,423 5.100% | 169,423 (New Position) | Filing History |